Literature DB >> 8642295

The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.

V Levitsky1, Q J Zhang, J Levitskaya, M G Masucci.   

Abstract

We have investigated the reactivity to two human histocompatibility leukocyte antigen (HLA) A11-restricted cytotoxic T lymphocyte (CTL) epitopes derived from amino acids 416-424 (IVTDFSVIK, designated IVT) and 399-408 (AVFDRKSVAK, designated AVF) of the Epstein-Barr virus (EBV) nuclear antigen (EBNA) 4. A strong predominance of CTL clones specific for the IVT epitope was demonstrated in polyclonal cultures generated by stimulation of lymphocytes from the EBV-seropositive donor BK with the autologous B95.8 virus-transformed lymphoblastoid cell line (LCL). This was not due to intrinsic differences of CTL efficiency since clones specific for the two epitopes lysed equally well A11-positive phytohemagglutinin blasts and LCLs pulsed with the relevant synthetic peptide. Irrespective of the endogenous levels of EBNA4 expression, untreated LCLs were lysed more efficiently by the IVT-specific effectors, suggesting that a higher density of A11-IVT complexes is presented at the cell surface. In accordance, 10-50-fold higher amounts of IVT peptides were found in high-performance liquid chromatography fractions of acid extracts corresponding to an abundance of about 350-12,800 IVT and 8-760 AVF molecules per cell. Peptide-mediated competition of CTL sensitization, transport assays in streptolysin-O permeabilized cells, and induction of A11 expression in the transporter associated with antigen presentation-deficient T2/A11 transfectant demonstrated that the IVT and AVF peptides bind with similar affinities to A11, are translocated with equal efficiency to the endoplasmic reticulum, and form complexes of comparable stability over a wide range of temperature and pH conditions. A rapid surface turnover of A11 molecules containing the AVF peptide was demonstrated in metabolically active T2/A11 cells corresponding to a half-life of approximately 3.5 as compared to approximately 2 h for molecules induced at 26 degrees C in the absence of exogenous peptides and >12 h for IVT-containing complexes. This difference in persistence is likely to determine the representation of individual class I-restricted CTL epitopes within the cell surface pool of molecules, and may be an important factor contributing to their immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642295      PMCID: PMC2192361          DOI: 10.1084/jem.183.3.915

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  Standards for total serum protein assays--a collaborative study.

Authors:  B T Doumas
Journal:  Clin Chem       Date:  1975-07       Impact factor: 8.327

2.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

3.  Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules.

Authors:  G Niedermann; S Butz; H G Ihlenfeldt; R Grimm; M Lucchiari; H Hoschützky; G Jung; B Maier; K Eichmann
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft.

Authors:  D H Crawford; J A Thomas; G Janossy; P Sweny; O N Fernando; J F Moorhead; J H Thompson
Journal:  Lancet       Date:  1980-06-21       Impact factor: 79.321

7.  T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.

Authors:  A B Rickinson; M Rowe; I J Hart; Q Y Yao; L E Henderson; H Rabin; M A Epstein
Journal:  Cell Immunol       Date:  1984-09       Impact factor: 4.868

8.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

9.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

10.  Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product.

Authors:  B Malone; T Lee; F Snyder
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

View more
  30 in total

1.  Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28.

Authors:  A J Johnson; M K Njenga; M J Hansen; S T Kuhns; L Chen; M Rodriguez; L R Pease
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.

Authors:  Ian A York; Michael A Brehm; Sophia Zendzian; Charles F Towne; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype.

Authors:  Lenong Li; Weifeng Chen; Marlene Bouvier
Journal:  Immunogenetics       Date:  2005-05-04       Impact factor: 2.846

4.  Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes.

Authors:  Michael Uhlin; Maria G Masucci; Victor Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

5.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

6.  Antigen kinetics determines immune reactivity.

Authors:  Pål Johansen; Tazio Storni; Lorna Rettig; Zhiyong Qiu; Ani Der-Sarkissian; Kent A Smith; Vania Manolova; Karl S Lang; Gabriela Senti; Beat Müllhaupt; Tilman Gerlach; Roberto F Speck; Adrian Bot; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

Review 7.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

9.  Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response.

Authors:  Sanda Remakus; Luis J Sigal
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

10.  HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Authors:  R S Midgley; A I Bell; Q Y Yao; D Croom-Carter; A D Hislop; B M Whitney; A T C Chan; P J Johnson; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.